Prospects for the development of long-acting formulations of human somatropin.
dc.contributor.author | Jostel, Andreas | |
dc.contributor.author | Shalet, Stephen M | |
dc.date.accessioned | 2009-07-06T09:02:09Z | |
dc.date.available | 2009-07-06T09:02:09Z | |
dc.date.issued | 2006 | |
dc.identifier.citation | Prospects for the development of long-acting formulations of human somatropin. 2006, 5 (3):139-45 Treat Endocrinol | en |
dc.identifier.issn | 1175-6349 | |
dc.identifier.pmid | 16677056 | |
dc.identifier.doi | 10.2165/00024677-200605030-00002 | |
dc.identifier.uri | http://hdl.handle.net/10541/72530 | |
dc.description.abstract | In healthy humans, growth hormone (GH) is secreted in distinct pulses with an underlying nyctohemeral pattern. Current forms of somatropin replacement are unable to closely mimic such a release pattern, but are still able to exert the beneficial action of GH. A limited number of short-term studies in rodents and humans suggest that longitudinal growth may be superior when somatropin is given with a pulsatile mode of administration, whereas hepatic insulin-like growth factor-I generation and beneficial changes in body composition appear to be equal or even enhanced with continuous somatropin administration.Recent developments in drug delivery technology have allowed the use of slow-release preparations of somatropin in humans. The most successful technology so far has been the encapsulation of somatropin molecules in poly(D,L-lactic-co-glycolic acid) biodegradable microspheres. Pharmacokinetic and pharmacodynamic data have been published on two such preparations; Nutropin Depot((R)) and hGH-Biosphere((R)). The latter has a superior release profile, but outcomes data from multicenter trials in both children and adults have been presented for the former: catch-up growth was observed in children, although to a lesser degree than historic comparative data obtained with the use of daily somatropin injections and the effects on metabolic derangements in GH-deficient patients appeared similar to those observed with daily injections. Improved sustained-release somatropin preparations will need further study of their long-term efficacy, but, if successful, will be highly attractive in terms of patient compliance and convenience. | |
dc.language.iso | en | en |
dc.subject | Human Growth Hormone | en |
dc.subject | Somatropin | en |
dc.subject | Treatment Outcome | en |
dc.title | Prospects for the development of long-acting formulations of human somatropin. | en |
dc.type | Article | en |
dc.contributor.department | Department of Endocrinology, Christie Hospital, Manchester, UK. | en |
dc.identifier.journal | Treatments in Endocrinology | en |
html.description.abstract | In healthy humans, growth hormone (GH) is secreted in distinct pulses with an underlying nyctohemeral pattern. Current forms of somatropin replacement are unable to closely mimic such a release pattern, but are still able to exert the beneficial action of GH. A limited number of short-term studies in rodents and humans suggest that longitudinal growth may be superior when somatropin is given with a pulsatile mode of administration, whereas hepatic insulin-like growth factor-I generation and beneficial changes in body composition appear to be equal or even enhanced with continuous somatropin administration.Recent developments in drug delivery technology have allowed the use of slow-release preparations of somatropin in humans. The most successful technology so far has been the encapsulation of somatropin molecules in poly(D,L-lactic-co-glycolic acid) biodegradable microspheres. Pharmacokinetic and pharmacodynamic data have been published on two such preparations; Nutropin Depot((R)) and hGH-Biosphere((R)). The latter has a superior release profile, but outcomes data from multicenter trials in both children and adults have been presented for the former: catch-up growth was observed in children, although to a lesser degree than historic comparative data obtained with the use of daily somatropin injections and the effects on metabolic derangements in GH-deficient patients appeared similar to those observed with daily injections. Improved sustained-release somatropin preparations will need further study of their long-term efficacy, but, if successful, will be highly attractive in terms of patient compliance and convenience. |